Abstract
Adenosine (Ado) is released in response to tissue injury, promotes hyperemia, and modulates inflammation. The proinflammatory effects of Ado, which are mediated by the A2B Ado receptor (AdoR), may exacerbate tissue damage. We hypothesized that selective blockade of the A2B AdoR with 3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione (GS-6201) during acute myocardial infarction (AMI) would reduce adverse cardiac remodeling. Male ICR mice underwent coronary artery ligation or sham surgery (n = 10–12 per group). The selective A2B AdoR antagonist GS-6201 (4 mg/kg) was given intraperitoneally twice daily starting immediately after surgery and continuing for 14 days. Transthoracic echocardiography was performed before surgery and after 7, 14, and 28 days. A subgroup of mice was killed 72 h after surgery, and the activity of caspase-1, a key proinflammatory mediator, was measured in the cardiac tissue. All sham-operated mice were alive at 4 weeks, whereas 50% of vehicle-treated mice and 75% of GS-6201-treated mice were alive at 4 weeks after surgery. Compared with vehicle, treatment with GS-6201 prevented caspase-1 activation in the heart at 72 h after AMI (P < 0.001) and significantly limited the increase in left ventricular (LV) end-diastolic diameter by 40% (P < 0.001), the decrease in LV ejection fraction by 18% (P < 0.01) and the changes in the myocardial performance index by 88% (P < 0.001) at 28 days after AMI. Selective blockade of A2B AdoR with GS-6201 reduces caspase-1 activity in the heart and leads to a more favorable cardiac remodeling after AMI in the mouse.
Footnotes
S.T. and H.Z. contributed equally to this work.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
ABBREVIATIONS:
- AMI
- acute myocardial infarction
- Ado
- adenosine
- AdoR
- Ado receptor
- Ant
- antagonist
- B-mode
- bidimensional mode
- ECL
- enhanced chemiluminescence
- GS-6201
- 3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione
- HR
- heart rate
- ICAM-1
- intercellular adhesion molecule-1
- IL
- interleukin
- LV
- left ventricular
- LVAWDT
- LV anterior wall diastolic thickness
- LVEDD
- LV end diastolic diameter
- LVEF
- LV ejection fraction
- LVESD
- LV end systolic diameter
- LVPSP
- LV peak systolic pressure
- LVPWDT
- LV posterior wall diastolic thickness
- MI
- myocardial infarction
- M-mode
- monodimensional mode
- MPI
- myocardial performance index
- MRS1754
- N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide
- RV
- right ventricular
- RVEDA
- RV end-diastolic area
- TAPSE
- tricuspid annular plane systolic excursion
- TNF-α
- tumor necrosis factor-α
- VCAM
- vascular cellular adhesion molecule.
- Received December 26, 2011.
- Accepted August 23, 2012.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|